Complete Pathologic Response to Cemiplimab in a Patient With Fungating Cutaneous Squamous Cell Carcinoma of the Forehead: A Case Report

Cutaneous squamous cell carcinoma (cSCC) is typically managed successfully with surgical excision, yet a subset of tumors exhibit aggressive behavior with regional and distant metastases. Until recently, systemic treatment options for advanced disease were limited. The introduction of immune checkpoint inhibitors has significantly expanded treatment options for unresectable and metastatic cSCC. We report the case of a man with rapidly progressive cSCC of the forehead with cervical lymph node involvement who demonstrated significant clinical and radiographic improvement following treatment with cemiplimab, a programmed cell death-1 (PD-1) inhibitor. Treatment was initiated for unresectable disease and resulted in marked tumor regression, allowing for subsequent surgical resection. Final pathology demonstrated no residual carcinoma, consistent with a complete pathologic response. This case highlights the potential role of PD-1 inhibition in downstaging advanced cSCC and enabling definitive surgical management.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-16
DOI
https://doi.org/10.7759/cureus.119781
Primary Topic
Nonmelanoma Skin Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Complete Pathologic Response to Cemiplimab in a Patient With Fungating Cutaneous Squamous Cell Carcinoma of the Forehead: A Case Report

Omar Maen Rashid, Richard Rubenstein, Brad P. Glick, Gili Amid-Toby
5 links
Cureus
Nonmelanoma Skin Cancer Studies
article

Complete Pathologic Response to Cemiplimab in a Patient With Fungating Cutaneous Squamous Cell Carcinoma of the Forehead: A Case Report

Omar Maen Rashid, Richard Rubenstein, Brad P. Glick, Gili Amid-Toby
article en

Abstract

Cutaneous squamous cell carcinoma (cSCC) is typically managed successfully with surgical excision, yet a subset of tumors exhibit aggressive behavior with regional and distant metastases. Until recently, systemic treatment options for advanced disease were limited. The introduction of immune checkpoint inhibitors has significantly expanded treatment options for unresectable and metastatic cSCC. We report the case of a man with rapidly progressive cSCC of the forehead with cervical lymph node involvement who demonstrated significant clinical and radiographic improvement following treatment with cemiplimab, a programmed cell death-1 (PD-1) inhibitor. Treatment was initiated for unresectable disease and resulted in marked tumor regression, allowing for subsequent surgical resection. Final pathology demonstrated no residual carcinoma, consistent with a complete pathologic response. This case highlights the potential role of PD-1 inhibition in downstaging advanced cSCC and enabling definitive surgical management.

Cureus
University of Miami (US), Palm Springs General Hospital (US)
Good health and well-being
Nonmelanoma Skin Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon